Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the cost effectiveness of Evusheld in the treatment of immuno-compromised persons with complex health needs against the cost of an admission to hospital, given the increase in COVID-19 hospital admissions and the pressure on the NHS.

The decision not to procure Evusheld for prevention through emergency routes is not based on cost considerations, but rather on independent clinical advice by RAPID C-19 (a multi-agency group) and a UK National Expert Policy Working Group. These groups considered a full range of evidence, including clinical trial data, in vitro analysis and emerging observational studies, as well as the epidemiological context of Omicron and wider policies in the Government’s pandemic response and recovery. Their conclusion is that there is insufficient evidence of benefit to recommend deployment at this time.

The National Institute for Health and Care Excellence (NICE) is now conducting a Health Technology Evaluation of Evusheld, which is the routine process for new medicines to be evaluated for clinical and cost effectiveness and will provide recommendations through NICE’s guidance on the use of Evusheld in the National Health Service.